• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does NHS Funding For REDEMPLO Change The Bull Case For Arrowhead Pharmaceuticals (ARWR)?

    Simply Wall St·11/05/2026 00:48:46
    Listen to the news
    • Arrowhead Pharmaceuticals reported that REDEMPLO (plozasiran) previously received UK marketing authorisation and is now funded by the NHS in England and Wales for adults with genetically confirmed Familial Chylomicronaemia Syndrome whose triglycerides remain very high despite diet and standard therapies.
    • This decision gives Arrowhead Pharmaceuticals its first NHS-backed commercial foothold for plozasiran in a rare disease setting. It turns a late-stage pipeline asset into a reimbursed treatment and creates a real test of demand, pricing and care pathways for future RNAi launches.
    • The focus now shifts to how Arrowhead Pharmaceuticals' investment narrative could be reshaped by REDEMPLO's NHS-backed entry into the FCS market.

    Scan how Arrowhead Pharmaceuticals fits alongside other rare disease players by reviewing the hand-picked 38 healthcare AI stocks that harness advanced technology to tackle complex conditions.

    Arrowhead Pharmaceuticals Investment Narrative Recap

    To own Arrowhead Pharmaceuticals, you need to buy into RNAi as a viable drug platform and a late stage pipeline that is still loss making but revenue producing. REDEMPLO’s NHS reimbursement starts to shift plozasiran from “pipeline” to “product”, although early FCS sales are unlikely to transform near term financials on their own.

    The more immediate swing factor remains execution on broader late stage programs and managing high R&D and SG&A while the business is unprofitable, with a reported net loss of US$319.955 million. Risks around partner milestones, regulatory decisions and competition in cardiometabolic RNAi still matter more than this single UK launch.

    The upcoming November 12, 2026 webcast on full year results now sits in a different context for Arrowhead Pharmaceuticals, because management can discuss REDEMPLO as an authorised and NHS funded rare disease therapy. That gives investors a first look at how the group plans to operationalise commercial RNAi rather than just partner it.

    You can listen for early color on FCS uptake, pricing assumptions and launch costs, as well as how learnings may inform future indications like severe hypertriglyceridaemia. The call may also clarify how REDEMPLO data from PALISADE feeds into discussions with other regulators, which links directly to the broader approval and reimbursement catalyst path investors are watching.

    Arrowhead Pharmaceuticals' outlook projects US$1.0 billion in revenue and US$176.0 million in earnings by 2029. This scenario assumes 15.7% annual revenue growth and an earnings increase of about US$496.0 million from the current loss of US$320.0 million.

    Uncover why Arrowhead Pharmaceuticals' fair value indicates a 79% potential upside to its current price, which could narrow quickly.

    NasdaqGS:ARWR 1-Year Stock Price Chart
    NasdaqGS:ARWR 1-Year Stock Price Chart

    Exploring Other Perspectives

    One big swing factor that bullish analysts highlight for Arrowhead Pharmaceuticals is the severe hypertriglyceridaemia expansion for plozasiran. Before this NHS decision, the most optimistic forecasts already pencilled in revenue growing about 31.7% a year and earnings at roughly US$143.5 million by 2029. You can treat those projections as one end of a wide opinion spectrum, then consider whether this fresh UK reimbursement news moves your own expectations closer to that view or leaves them unchanged.

    Explore 3 other Arrowhead Pharmaceuticals fair value estimates, including one that suggests potential upside of up to 334% from the current price.

    Form Your Own Verdict

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Ideas Beyond Arrowhead Pharmaceuticals?

    If you want to stress test your thesis on Arrowhead Pharmaceuticals, it helps to compare it with a wider mix of businesses that share some of the traits you care about. The Simply Wall St screener lets you do exactly that in a structured way instead of relying on headlines or hunches.